David B Gernes

Learn More
The HeartMate family of implanted left ventricular assist devices (LVADs) developed by Thermo Cardiosystems, Inc. (TCI) span a time frame that goes back to the beginning of clinical use of mechanical circulatory support and will stretch well into the foreseeable future. Associated blood pump technology employed in the HeartMates range from an original(More)
Temporary and permanent ventricular assist systems, developed by Thermedics, Inc., are described, including rationale, design, operation and surgical applications. Clinical data are presented for pneumatically driven temporary left ventricular assist devices (LVAD). Usefulness of this device rests on the assumption that tissue of a weakened heart can(More)
A long-term, compact left ventricular assist device (LVAD), the HeartMate III, has been designed and fabricated, featuring a centrifugal pump with a magnetically levitated rotor. The pump has been optimized by in vitro testing to achieve a design point of 7 L/min against 135 mm Hg at high hydrodynamic efficiency (30%) and to be capable of up to 10 L/min(More)
A compact implantable centrifugal left ventricular assist device (LVAD) (HeartMate III) featuring a magnetically levitated impeller is under development. The goal of our ongoing work is to demonstrate feasibility, low hemolysis, and low thrombogenicity of the titanium pump in chronic bovine in vivo studies. The LVAD is based on so-called bearingless motor(More)
Craig W. Sherman The VVD expands and collapses as the pump fills and ejects David Gernes blood, respectively, preventing the formation of high positive Warren Clay and negative air pressures as the diaphragm moves up and Victor Poirier down. The TET system inductively couples the energy stored William F. Bernhard in the external powerpack into the body and(More)
Marked improvements were realized in the development of electrically driven left ventricular assist systems. A volume reduction of 46%, a system weight reduction of 63%, and a factor of 2 improvement in overall efficiency (29%) were realized. The system, operating at a pressure of 120 mm Hg with a flow rate of approximately 7 L, requires only 7.5 W of input(More)
The promise of expanded indications for left ventricular assist devices in the future for very long-term applications (10+ years) prompts sealed (i.e. fully implanted) systems and less-obtrusive and more reliable implanted components than their external counterparts in percutaneous configurations. Furthermore, sealed systems increase the fraction of total(More)
  • 1